Cargando…

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres

AIMS: Guideline recommendations highlight the critical role of combination therapy for the treatment of pulmonary arterial hypertension (PAH). Conversely, registry data demonstrate that a considerable number of PAH patients remain on monotherapy. The reasons for this discrepancy remain elusive. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wissmüller, Max, Xanthouli, Panagiota, Benjamin, Nicola, Grünig, Ekkehard, Richter, Manuel J., Gall, Henning, Ghofrani, Hossein Ardeschir, Herkenrath, Simon, Skowasch, Dirk, Pizarro, Carmen, Halank, Michael, Hohmann, Christopher, Hellmich, Martin, Gerhardt, Felix, Rosenkranz, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715885/ https://www.ncbi.nlm.nih.gov/pubmed/35706353 http://dx.doi.org/10.1002/ehf2.13804

Ejemplares similares

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study
por: Yogeswaran, Athiththan, et al.
Publicado: (2020)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2022)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension
por: Grimminger, Jan, et al.
Publicado: (2017)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
por: Schmidt, Kai-Helge, et al.
Publicado: (2023)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
por: Cartin-Ceba, Rodrigo, et al.
Publicado: (2018)

Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension
por: Richter, Manuel Jonas, et al.
Publicado: (2016)

Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study
por: Kramer, Tilmann, et al.
Publicado: (2021)

Incidence and prognostic significance of malignant arrhythmias during (repetitive) Holter electrocardiograms in patients with pulmonary hypertension
por: Bandorski, Dirk, et al.
Publicado: (2023)

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
por: Eichstaedt, Christina A., et al.
Publicado: (2020)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri(®)): a prospective, 6-months, open label, observational, non-interventional study
por: Degering, Julia, et al.
Publicado: (2023)

Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
por: Stubbe, Beate, et al.
Publicado: (2021)

Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
por: Pfarr, Nicole, et al.
Publicado: (2011)

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study
por: Konstantinides, Stavros V., et al.
Publicado: (2016)

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
por: Xanthouli, Panagiota, et al.
Publicado: (2020)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

Estimated plasma volume status: association with congestion, cardiorenal syndrome and prognosis in precapillary pulmonary hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2023)

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
por: Hoeper, Marius M., et al.
Publicado: (2022)

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
por: Hoeper, Marius M., et al.
Publicado: (2022)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016)

Modulating cGMP to Treat Lung Diseases
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2009)

The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial
por: Ehlken, Nicola, et al.
Publicado: (2016)

Exercise Training Improves Exercise Capacity and Quality of Life in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension
por: Nagel, Christian, et al.
Publicado: (2012)

Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic
por: Dobler, Carolin Leoni, et al.
Publicado: (2020)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension
por: Gall, Henning, et al.
Publicado: (2021)

Hepatorenal dysfunction in patients with chronic thromboembolic pulmonary hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2023)

Improved Survival for Patients with Systemic Sclerosis–associated Pulmonary Arterial Hypertension: For Real?
por: Xanthouli, Panagiota
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qi60e21b8g5n5e9scd03tcfktc